Reading IGC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IGC free→
IGC PHARMA INC (IGC)
AMEXHealth CareBiotechnologySnapshot 2026-06-16
Watch· this week
$0.280.00%
Close 2026-06-16 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady. Risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 85% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
as of 2026-06-16
Quick facts
- Exchange
- AMEX
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $28.03M
- Employees
- —
- IPO date
- 2005-05-13
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $0.28. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$0.15consensus
Range $0.13 – $0.16
vs price: +92% above
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearfull
$0.27consensus
Range $0.25 – $0.30
vs price: +3% above
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Re-ratinglow confidence
At $0.28 IGC trades at 22× p/s — 2.3× the 10× p/s peer median. The market is re-rating it beyond its own range; our $0.15 fair value is low-confidence here. Not investment advice.
Multiple (P/S)
22.0x
peer 9.6x · own history —
Premium
2.3x peer
Growth the price needs
89%
our forecast 20%
Our fair value
$0.15
range $0.14 – $0.16
WhyPeer anchor understates a real premiumEarnings too small for P/E
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiveexpensive — growth-justified12-month view
What's priced inUnjustified
The market is pricing in roughly 89% near-term growth, well above our forecast of about 20%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Low fragilityrisk posture, not a price call
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
Historical context
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
weakOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
9th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 0.76x of net income into operating cash flow.
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity.
Management & capital allocation
neutral8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
44th pctl · Health Care
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Neutral1 positive, 1 negative material events / 30dfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.02 → $-0.02 (+0.0% / 30d). 0 raised, 0 cut, 2 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
Material events
1 positive, 1 negative / 30d. See F4 management tile for the event list.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: by revenue growth.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: neutral
- Capital allocation
- weak
- Earnings discipline
- strong
- Margin discipline
- neutral
- Balance sheet
- weak
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-16
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$195.
How much price usually moves either way.
On a bad day, this stock has moved -$513.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,715.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- score change · management_scoremoderate change
Management rose by 18.3 points (from 25.5 to 43.8).
- label change · confidence_labelsmall change
Confidence changed from 'medium' to 'high'.
As of June 16, 2026, management rose. Confidence changed to high. These changes indicate a shift in the perception of management effectiveness and overall confidence in the company.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for IGC yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting IGC and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for IGC and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping IGC and other Healthcare names could fade. Watch these names for early warning.
- If GDP growth slows materially from the current 2.6% (say, below 2%), it hits IGC and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
- If inflation reaccelerates, say headline CPI back above 3.5% (currently 2.8%), that would delay Fed rate cuts, which is a drag on IGC and other Healthcare names.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-089d agoItem 1.01
Entry into a Material Definitive Agreement Extension of Master Loan and Security Agreement On June 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the “Loan Agreement”) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the “Lender”). The Loan Agreement continues the facility arrangement previously s…
M&A activitypositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-2.1 vs last weeklatest as of 2026-06-17
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.